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Atrial-Selective Approaches
for the Treatment of Atrial Fibrillation
Joachim R. Ehrlich, MD,* Peter Biliczki, MD, PHD,* Stefan H. Hohnloser, MD, FACC,*
Stanley Nattel, MD, FACC†
Frankfurt, Germany; and Montreal, Quebec, Canada
Atrial-selective pharmacologic approaches represent promising novel therapeutic options for the treatment of
atrial fibrillation (AF). Medical treatment for AF is still more widely applied than interventional therapies but is
hampered by several important weaknesses. Besides limited clinical efficacy (cardioversion success and sinus-
rhythm maintenance), side effects like ventricular proarrhythmia and negative inotropy are important limitations
to present class I and III drug therapy. Although no statistically significant detrimental survival consequences
have been documented in trials, constitutional adverse effects might also limit applicability. Cardiac targets for
novel atrial-selective antiarrhythmic compounds have been identified, and a large-scale search for safe and ef-
fective medications has begun. Several ionic currents (IKACh, IKur) and connexins (Cx-40) are potential targets,
because atrial-selective expression makes them attractive in terms of reduced ventricular side-effect liability.
Data on most agents are still experimental, but some clinical findings are available. Atrial fibrillation generates a
specifically remodeled atrial milieu for which other therapeutic interventions might be effective. Some drugs
show frequency-dependent action, whereas others target structurally remodeled atria. This review focuses on
potential atrial-selective compounds, summarizing mechanisms of action in vitro and in vivo. It also mentions
favorable interventions on the milieu in terms of conventional (such as antifibrotic effects of angiotensin-system
antagonism) and innovative gene-therapy approaches that might add to future AF therapeutic options. (J Am
Coll Cardiol 2008;51:787–92) © 2008 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2007.08.067t
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anvasive electrophysiological procedures such as pulmonary
ein or left-atrial circumferential ablation represent prom-
sing approaches to atrial fibrillation (AF) treatment. Al-
hough these therapeutic options are being optimized,
edical therapy remains the standard initial treatment for
ost patients (1). The impact of AF on public health is
remendous, given its influence on quality of life, morbidity,
nd mortality. Atrial fibrillation affects a constantly increas-
ng number of individuals as populations age.
Pharmacologic approaches to AF have traditionally ap-
lied antiarrhythmic agents originally developed to treat
entricular arrhythmias. Perhaps because of this, they tend
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ccepted August 13, 2007.o have prominent ventricular effects and risks of ventricular
roarrhythmia.
ationale for Atrial-Selective AF Therapy
aughan–Williams antiarrhythmic drug classes I and III
ight convert AF and prevent relapses after cardiover-
ion, but clinical efficacy and tolerability are limited.
entricular side effects that limit applicability include
roarrhythmic events and negative inotropy. Although no
verall detrimental effect on survival was found in AF-
IRM (Atrial Fibrillation Follow-up Investigation of
hythm Management), a possible excess of non-
ardiovascular deaths poses a potentially serious addi-
ional caveat (2).
Class I agents inhibit sodium (Na)-current and suppress
F by reducing excitability and destabilizing re-entrant
otors (3). Class III drugs like d,l-sotalol and amiodarone
re used for AF-prevention after cardioversion with success
ates of approximately 50% to 80% after 1 year (4). Except
or amiodarone (for which noncardiac side effects are
rominent), most class III agents have a significant risk of
entricular proarrhythmia (5). Class III drugs prolong
ction potential duration (APD) by blocking the rapid
elayed-rectifier potassium current (IKr) (6). Rapid delayed-
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Atrial-Selective Approaches February 26, 2008:787–92rectifier potassium current is im-
portant for both atrial and ven-
tricular repolarization, and
blocking IKr increases the QT-
interval and risks causing tor-
sades de pointes arrhythmias.
Potential Targets for
Atrial-Selective Therapy
Ion-channel targets. Modula-
tion of atrially expressed ion-
channel proteins has emerged as a
novel therapeutic concept: anti-
arrhythmic agents that target such
channels/proteins are termed
“atrial-selective” drugs. Currents
like the ultrarapid delayed-rectifier
(IKur) and acetylcholine-regulated
current (IKACh) are expressed in
atrial but not ventricular cells and
therefore are of potential interest
(Fig. 1). Truly specific modulators
f cardiac ion-channels or structure are unavailable. Most drugs
re 1 or 2 orders of magnitude more effective in inhibiting the
arget of interest (Fig. 2) compared with other potential targets.
Abbreviations
and Acronyms
AF  atrial fibrillation
AP  action potential
APD  action potential
duration
Cx  connexin
DPO  diphenylphosphine
oxide
ERP  effective refractory
period
IKACh  acetylcholine-
regulated potassium
current
IKr  rapid delayed-rectifier
potassium current
IKur  ultrarapid delayed-
rectifier potassium current
INa  sodium current
SAC  stretch-activated
channel
Figure 1 Regional Difference in
Ionic Current Contribution to APs
Differences in key ion currents between atrial (blue) and ventricular (red)
action potentials (APs). Atrial APs have smaller AP amplitude and less negative
resting membrane potential. Currents (green) identified above the line illustrat-
ing the APs are present in both regions; atrially expressed ionic currents are
illustrated below the AP schematic (blue). IKACh  acetylcholine-regulated
potassium current; IKur  ultrarapid delayed-rectifier potassium current; INa 
sodium current.aKACh. The inwardly rectifying IKACh mediates vagal influ-
nces on heart rate and atrial repolarization. Pore-forming
ir3 alpha-subunits are prominently expressed in sinus,
trio-ventricular nodes, and atrial myocardium but are
argely absent in ventricles (7). The IKACh activation short-
ns APD and causes hyperpolarization. Kir3.1 messenger
ibonucleic acid (mRNA) is downregulated, and the re-
ponse to acetylcholine is blunted in AF (8). In contrast,
ncreases in the constitutively active (i.e., active in the
bsence of agonist) form of this current contribute to
F-related electrical remodeling (9–11). Because of this
pregulation of constitutive IKACh, IKACh inhibition causes
ubstantial APD prolongation and atrial tachyarrhythmia
ermination in the presence of atrial remodeling (11).
Kur. This current is called “ultrarapid” because it activates
orders of magnitude faster than IKr. Ultrarapid delayed-
ectifier potassium current is carried by Kv1.5 alpha-
ubunits and is present in human atrial but not ventricular
ells (12–14). One study demonstrated reduced IKur with
uman AF (15), which could limit the efficacy of IKur
nhibition, but this result was not confirmed by subse-
uent investigations (16,17). The effects of IKur inhibi-
ion on atrial repolarization depend strongly on action
otential (AP) morphology, with the brief, triangular
Ps during AF being particularly susceptible to prolon-
ation by IKur inhibition (18).
trially expressed connexins. Connexin (Cx)-40 and
x-43 are the 2 connexins present in the atrium: Cx-43 is
xpressed throughout the heart, but Cx-40 expression is
estricted to atria and conducting system (19). Connexin-40
nockout-mice exhibit prolonged P waves and susceptibility
o atrial arrhythmias (20). Cardiac-specific mutations in
JA5 (encoding Cx40) lead to idiopathic AF (21). Connex-
ns are remodeled in AF, but different studies have provided
idely discrepant results (22).
odium current. Atrial sodium current (INa)-block termi-
ates AF by destabilizing AF-maintaining re-entrant rotors
3). Although atrial and ventricular Na-channels have the
ame principal Na-channel alpha-subunit (Nav1.5), dif-
erences in beta-subunits could convey drug selectivity.
tate-dependent INa-block could produce blocking selectiv-
ty for rapid rates like those of AF or for atrial APs (23).
ome atrial-selective agents (like vernakalant) might achieve
F termination and atrial selectivity by rapidly unbinding
Na antagonism (24).
tretch-activated channels. Atrial fibrillation is com-
only associated with conditions that increase left-atrial
ressure like heart failure or valvular heart disease. Left-
trial enlargement is common in AF and makes the arrhyth-
ia harder to control. Cellular stretch activates stretch-
ctivated nonselective cation channels (SACs). The peptide
AC-inhibitor GsMTx4 (a tarantula-spider venom toxin)
uppresses AF in a rabbit atrial-stretch model (25).
onion-channel targets. Modulation of atrial-structure
hanges associated with AF might represent an interesting
pproach to AF treatment devoid of proarrhythmic poten-
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February 26, 2008:787–92 Atrial-Selective Approachesial. Tissue fibrosis is a prominent feature of AF-promoting
emodeling in heart failure (26,27), with little reversal even
fter hemodynamic recovery (28). Atrial extracellular matrix
emodeling is associated with AF persistence (29). Experi-
ental and clinical studies suggest potential benefits of
ngiotensin-system inhibition, possibly via suppression of
tructural remodeling (30,31). Patients treated with the
ngiotensin-receptor antagonist irbesartan showed a dose-
elated reduction in AF recurrences (32,33). Very rapid
trial tachycardia, as accompanies AF, remodels atrial elec-
rical properties and promotes AF; drugs that prevent such
emodeling might be useful in AF management (22,23).
ecause of space limitations, this paper will not deal in
etail with nonion-channel targets. The interested reader is
eferred to recent reviews (1,23,31,34).
rugs in Development
KACh inhibitors. Purely selective IKACh inhibitors are
urrently unavailable for clinical use. Tertiapin-Q is a
onoxidizable derivative of the naturally occurring peptide-
oxin tertiapin that selectively and potently inhibits Kir3 and
ir1 channels (35,36). Because there are no significant
ardiomyocyte Kir1 channels, the drug is highly selective for
KACh (Kir3.1/3.4) in cardiac tissue. The background
nward-rectifier current IK1 (Kir2 channels) remains unaf-
ected (36). Tertiapin-Q inhibits constitutively active IKACh
t low-nanomolar concentrations (9,10). Tertiapin-Q ter-
inates atrial tachyarrhythmias in tachycardia-remodeled
reparations without altering ventricular repolarization
Figure 2 Targets of “Atrial-Selective” Antiarrhythmic Drugs
This figure presents a simplified cell with sarcolemmal membrane and ion currents
macologic agents discussed in the paper are presented in boxes, and filled arrow
illustrated by the “” symbol. JTV-519 stabilizes ryanodine-receptor (RyR) and cal
other abbreviations as in Figure 1.9,11). Intravenous tertiapin terminates vagally induced and sconitine-dependent AF in dogs (37). The practical devel-
pment of IKACh-blockers for AF therapy will require
voidance of collateral vagolytic side-effects due to IKACh
nhibition in other systems.
NIP-142 inhibits heterologously expressed Kir3.1/3.4
urrent (reconstituting IKACh) as well as Kv1.5 current
38,39). It terminates vagal AF and prevents AF reinduction
40). NIP-141 (a hydrochloride-bound form of NIP-142)
locks human atrial transient outward current (Ito) and IKur
ith low-micromolar half-inhibitory concentration (IC50)
41). Although combined IKACh and IKur block make this
rug interesting, it is not strictly atrial-selective, possibly
ecause of IKr and Ito inhibition (40). NIP-151 is a more
elective IKACh-blocker with interesting preliminary evi-
ence for efficacy against experimental AF (23).
JTV-519 (also known as K-201) is a drug with vasodi-
ating properties that also has IKACh-blocking actions and
n ability to stabilize calstabin-ryanodine receptor-binding
23). JTV-519 suppresses AF inducibility while prolonging
trial effective refractory period (ERP) (42,43). However,
he drug also has actions on INa, ICa, IK1, and IKr (44).
Kur inhibitors. IKur was the first ion-channel proposed as
n atrial-selective target (12), and a series of IKur-blocking
rugs has been developed.
AVE0118 targets Ito/IKur and has additional IKACh-
locking properties (45,46). AVE0118 decreases left-atrial
ulnerability to AF induction and AF reinducibility after
ardioversion from persistent AF without prolonging QT
ntervals (47,48), but its clinical development has been
ransporters that have served as targets for atrial-selective therapy shown. Phar-
te inhibition of specific currents. Rotigaptide is a connexin (Cx) activator—as
complexes. DPO  diphenylphosphine oxide; SR  sarcoplasmic reticulum;and t
s deno
stabintopped for undisclosed reasons. AVE1231 is a congener
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Atrial-Selective Approaches February 26, 2008:787–92ith improved pharmacokinetics and similar Kv1.5-
locking properties that also exhibits atrial selectivity (49).
Diphenylphosphine oxide (DPO) compounds inhibit
eterologous hKv1.5 currents as well as human atrial IKur at
ow-micromolar concentrations (50). The DPO-1 inhibits
Kur approximately 20-fold more effectively than IKr or IKs
nd approximately 8-fold more than Ito, while selectively
rolonging human atrial versus ventricular APs. In an
nimal model of atrial flutter, DPO-1–induced atrial-ERP
rolongation terminates arrhythmia without affecting QT
ntervals (51).
The synthesis of many other Kv1.5-inhibiting substances
as recently been described. Experimental characterization
f such agents, including 2-aminoalkylethers, aryl-
ulfonamide-indane, and psoralen derivatives, has been
nitiated (52–54).
x activators. Abnormalities in connexin expression and
unction accompany AF-promoting remodeling due to
eart failure and atrial tachyarrhythmias (23). Atrial fibril-
ation is a recognized complication of myocardial infarction
55,56), and acute atrial ischemia promotes AF mainte-
ance (56). Ischemia-induced cellular acidification causes
rrhythmogenic gap-junctional uncoupling (57). The pep-
ide rotigaptide enhances gap-junction conductivity and
revents intercellular uncoupling (57). In AF related to
trial dilation, rotigaptide reversed atrial conduction slowing
ut failed to prevent AF (58). Recent work in canine AF
odels shows no efficacy for AF related to electrical and
tructural remodeling but effectiveness in ischemic AF and
itral-valve disease (59).
trial-selective agents of uncertain mechanism. Several
gents have atrial-selective action of uncertain ionic mech-
nism. AZD7009 is a multi-channel blocker that terminates
xperimental AF in a sterile pericarditis model with minor
T interval prolongation (approximately 9%) (60).
ZD7009 is approximately equally potent at inhibiting
Kv1.5 and hKv4.3/hKChIP2.2-currents (61) and is also an
pen-channel HERG (IKr)-current blocker (62). A com-
ined in vivo and in vitro evaluation of AZD7009 showed
PD prolongation and evidence of frequency-dependent
Na inhibition (63). Atrial ERP was prolonged in vivo with
arginal (nonsignificant) effects on ventricular tissue. How-
ver, clear ventricular effects in vitro raised questions about
trial selectivity. AZD7009, azimilide (inhibitor of IKs, IKr,
nd ICa,L), and AVE0118 reduce AF inducibility to the
ame extent in acutely dilated rabbit atria (64). AZD7009
ncreased atrial ERP more in dilated than nondilated atria,
ossibly owing to INa inhibition, and has proven safe and
ffective in cardioverting persistent clinical AF (65).
Vernakalant (formerly RSD1235) blocks Kv1.5, Ito,
ERG, and Na current (24). INa-block shows rapid
esting-state unbinding and is frequency-dependent. De-
pite its large pharmacologic spectrum of activity, experi-
ental data suggest that vernakalant’s AF-selective actions
ight be based on state-dependent INa blockade (23). In aandomized, placebo-controlled study of patients with t72-h duration AF (66), vernakalant terminated AF in
1% of subjects with a median conversion time of 14 min
vs. 5% and 162 min for placebo). The QTc and QRS
uration were nonsignificantly prolonged. Intravenous ver-
akalant is in late-stage clinical development, and an oral
ormulation is in phase II trials.
ene Therapy
ene therapy approaches promise greater selectivity than
lassical small-molecule drugs and represent a rapidly ex-
anding field of research. Proof-of-principle for gene ther-
py in AF was provided by studies showing that transferring
he gene encoding constitutively active inhibitory G-protein
nto the AV node controls ventricular response-rate and
everses tachycardiomyopathy in pigs with AF (67). Selec-
ive transmural atrial-refractoriness prolongation has been
chieved by a novel approach to local application of an
denovirus carrying a dominant-negative mutated HERG
onstruct (68).
MicroRNA (mir) represents another recently discovered
ene-therapy target. Mir-1 seems involved in regulating
ardiac conduction and modulates KCNJ1 and GJA1 tran-
cription in human coronary artery disease (69,70). Because
JA1 encodes Cx43, it might be relevant to AF, and
icroRNA designed to enhance Cx40-expression could be
aluable for atrial-selective therapy. Modulation of cardiac
on-channel genes (KCNQ1, KCNE1, HCN2, HCN4) by
ir-1 and -133 might represent an alternative approach to
egulation of AV-nodal conduction or atrial excitability
71,72). This emerging field needs to be explored further
efore therapeutic applications are fully appreciated.
Many obstacles to gene therapy remain to be overcome,
ncluding effective local gene-delivery approaches, stable
ene incorporation, control over the level and distribution of
ene expression, avoidance of inflammatory reactions and
ther adverse effects of vectors, and so forth. Nevertheless,
ene therapy remains a very novel and potentially promising
herapeutic approach.
ummary and Conclusions
he development of novel antiarrhythmic agents promises
o expand the range of AF pharmacotherapy. Although
urely selective atrial antiarrhythmic agents are not avail-
ble, many candidate drugs demonstrate relative selectivity.
ome ion-channels, notably IKur and IKACh, are selectively
xpressed in atrium versus ventricle, but it remains to be
hown that blocking them conveys antiarrhythmic action
ith a desirable lack of side effects in man. Connexin
odulation might be interesting, but efficacy depends
trongly on AF mechanisms, and thus far the requirement
or intravenous administration limits applicability. State-
elective INa blockade might allow AF-suppression without
he proarrhythmic complications that plagued classical INa-
lockers. Some drugs have atrial-selective actions and an-
iAF efficacy of uncertain mechanism; further research
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February 26, 2008:787–92 Atrial-Selective Approachesight provide useful mechanistic clues for novel-compound
evelopment. Gene-therapy approaches are still in their
nfancy but might provide important advantages.
It is too early to be sure whether the concept of atrial-
elective drug therapy will translate into safer and more
ffective ways of maintaining sinus rhythm, but the range of
ovel targets under investigation provides hope for the
uture. Most studies to date have been experimental but
ave paved the way for clinical trials that will hopefully soon
onfirm the safety, efficacy, and applicability of this ap-
roach.
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